Related references
Note: Only part of the references are listed.Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
Ying Jin et al.
CLINICAL CANCER RESEARCH (2022)
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
Carl M. Gay et al.
CANCER CELL (2021)
Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer
Joseph M. Chan et al.
CANCER CELL (2021)
Small-cell lung cancer
Charles M. Rudin et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer
Alexandre F. Aissa et al.
NATURE COMMUNICATIONS (2021)
Integrated Single-Cell Atlas of Endothelial Cells of the Human Lung
Jonas C. Schupp et al.
CIRCULATION (2021)
Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation
Alvaro Quintanal-Villalonga et al.
CANCER DISCOVERY (2021)
New Approaches to SCLC Therapy: From the Laboratory to the Clinic
John T. Poirier et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate
Abbie S. Ireland et al.
CANCER CELL (2020)
Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma
Nayoung Kim et al.
NATURE COMMUNICATIONS (2020)
SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures
Camille Tlemsani et al.
CELL REPORTS (2020)
Next-generation characterization of the Cancer Cell Line Encyclopedia
Mahmoud Ghandi et al.
NATURE (2019)
Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges
A. Pavan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET (2019)
POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer
Yu-Han Huang et al.
GENES & DEVELOPMENT (2018)
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
M. Catherine Pietanza et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Andrew Butler et al.
NATURE BIOTECHNOLOGY (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes
Wei Zhang et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer
L. L. da Motta et al.
ONCOGENE (2017)
Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas
June-Koo Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Single-cell mRNA quantification and differential analysis with Census
Xiaojie Qiu et al.
NATURE METHODS (2017)
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition
Gurkan Mollaoglu et al.
CANCER CELL (2017)
The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma
Hemant K. Bid et al.
MOLECULAR CANCER THERAPEUTICS (2016)
ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs
Mark D. Borromeo et al.
CELL REPORTS (2016)
Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression
Ryan Lenhart et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Comprehensive genomic profiles of small cell lung cancer
Julie George et al.
NATURE (2015)
limma powers differential expression analyses for RNA-sequencing and microarray studies
Matthew E. Ritchie et al.
NUCLEIC ACIDS RESEARCH (2015)
The Molecular Signatures Database Hallmark Gene Set Collection
Arthur Liberzon et al.
CELL SYSTEMS (2015)
A Role for Partial Endothelial-Mesenchymal Transitions in Angiogenesis?
Katrina M. Welch-Reardon et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
GSVA: gene set variation analysis for microarray and RNA-Seq data
Sonja Haenzelmann et al.
BMC BIOINFORMATICS (2013)
NanoStringNorm: an extensible R package for the pre-processing of NanoString mRNA and miRNA data
Daryl Waggott et al.
BIOINFORMATICS (2012)
Comprehensive genomic characterization of squamous cell lung cancers
Peter S. Hammerman et al.
NATURE (2012)
Removing Batch Effects in Analysis of Expression Microarray Data: An Evaluation of Six Batch Adjustment Methods
Chao Chen et al.
PLOS ONE (2011)
Inositol 1,4,5-trisphosphate (IP3) receptor type1 (IP3R1) modulates the acouisition of cisplatin resistance in bladder cancer cell lines
T Tsunoda et al.
ONCOGENE (2005)
KEGG: Kyoto Encyclopedia of Genes and Genomes
M Kanehisa et al.
NUCLEIC ACIDS RESEARCH (2000)
Share Paper
